

1 **Third vaccine doses could have indirectly averted >100,000 deaths in the USA by reducing**  
2 **transmission of the SARS-CoV-2 Delta variant**

3 Billy J. Gardner\*, A. Marm Kilpatrick\*

4

5 *Department of Ecology and Evolutionary Biology, University of California, Santa Cruz, Santa*  
6 *Cruz, California, 95064 USA*

7 *\*To whom correspondence should be addressed: [wjgyc14@gmail.com](mailto:wjgyc14@gmail.com); [akilpatr@ucsc.edu](mailto:akilpatr@ucsc.edu)*

8 A. Marm Kilpatrick

9 130 McAllister Way

10 EE Biology/CBB

11 University of California

12 Santa Cruz, CA 95060

13 **Preprint Server:** medRxiv: <https://www.medrxiv.org/content/10.1101/2021.10.25.21265500>

14 **Classification** Biological Sciences: Applied Biological Sciences

15 **Keywords** COVID-19; vaccine effectiveness, surrogates of protection, vaccination; waning  
16 immunity; herd immunity, modeling

17

## 18 **Abstract**

19 Vaccination programs often focus on direct protection of individuals against disease and discount  
20 reductions in transmission, which can result in preventable disease and death. Initial clinical  
21 trials for most COVID-19 vaccines only measured direct protection, and dosing and vaccine  
22 selection decisions have, so far, ignored effects on transmission. Here we provide an empirical  
23 framework for incorporating indirect effects of COVID-19 vaccination on transmission in a  
24 continuous dynamic immune landscape. For the first time, we quantified relationships between  
25 neutralizing antibody titers and vaccine effectiveness for both susceptibility ( $VE_s$ ) and  
26 infectiousness ( $VE_i$ ) and quantified changes in  $VE$  with waning and boosting of immunity. We  
27 used these relationships to quantify the impact that additional doses of mRNA vaccines  
28 (BNT162b2 and mRNA-1273) could have had in reducing transmission and deaths caused by the  
29 deadliest SARS-CoV-2 variant, Delta, in Autumn 2021. Neutralizing antibodies waned 8-fold in  
30 2021 over the six months following initial vaccination with mRNA vaccines, which reduced  $VE_s$   
31 33-38% (from 75-81% to 47-54%) and  $VE_i$  62-65% (from 47-57% to 16-22%) against the Delta  
32 variant. Third doses increased neutralizing antibody titers 13-26-fold, which more than restored  
33  $VE$  and reduced the relative risk of transmission 7-10-fold. Administering third doses by  
34 September 1, 2021 could have reduced the effective reproductive number  $R_t$  by 19%, stopped  
35 surges in transmission in many populations, and averted an estimated 111,491 deaths in the  
36 United States. Vaccination programs that incorporate effects on transmission in trial design,  
37 vaccination frequency, and vaccine choice are needed to address current and future public health  
38 challenges.

39

40

41 **Significance**

42 Vaccination programs for many diseases often focus primarily on people at risk of severe disease  
43 and sometimes discount indirect reductions in transmission. We developed a framework for  
44 estimating the effects of vaccination on transmission and used it to estimate the number of  
45 COVID-19 deaths that could have been averted by deploying third doses during the Delta variant  
46 surge to reduce transmission. We show that immunity against transmission had waned  
47 significantly in late 2021. However, widespread deployment of third doses could have restored  
48 protection, stopped surges of the Delta variant, and prevented more than 100,000 deaths in the  
49 United States. Vaccination programs should incorporate effects on transmission in initial trial  
50 design, vaccination frequency, and vaccine selection to address public health challenges.

51

## 52 **Introduction**

53           Vaccination is the most effective tool for reducing disease, hospitalizations, and deaths  
54 for many infectious diseases <sup>1-5</sup>. Core components of vaccination programs include how to  
55 allocate vaccine doses within and between individuals, when to recommend new doses and,  
56 when multiple vaccines are available, which vaccines to recommend. In making these decisions  
57 and developing new vaccines, public health agencies often focus on the direct impact of vaccines  
58 in reducing disease in vaccinated individuals <sup>6,7</sup>. For example, the United States Food and Drug  
59 Administration guidelines for randomized control trials for COVID-19 vaccines did not include  
60 any criteria regarding protection against infection or reductions in infectiousness <sup>8</sup>, and, as a  
61 result, these weren't measured in the US trials for mRNA vaccines made by Pfizer-BioNTech  
62 and Moderna. Similarly, vaccines are often only recommended for subsets of the population at  
63 high risk disease severity <sup>9</sup>, despite the fact that in many cases, such as pneumococcal disease,  
64 vaccines have been shown to reduce transmission <sup>10</sup>.

65           Many vaccines can have population-wide benefits by reducing transmission either by  
66 reducing susceptibility or reducing infectiousness (i.e. transmission from breakthrough  
67 infections), or both, which indirectly protects additional individuals <sup>11</sup>. In these cases,  
68 vaccinating individuals who are not at risk of severe disease can reduce severe disease through  
69 reductions in transmission <sup>12</sup>. Deploying vaccines to reduce transmission can increase health  
70 equity by reducing infection in individuals that lack access to health care, including vaccination,  
71 which is a key global challenge <sup>13</sup>. However, determining whether the benefits of deploying  
72 vaccines to reduce transmission is warranted requires estimating vaccine effectiveness (VE) for  
73 transmission and the potential number of deaths averted for a specific population, which, in turn,  
74 depends on the dynamic levels of population immunity for the pathogen in question.

75           The emergence of the Delta variant (B.1.617.2) of SARS-CoV-2 in 2021 illustrates the  
76 potential benefit of using vaccination to reduce transmission. The Delta variant caused a surge of  
77 deaths globally, even in populations with high initial two-dose vaccination coverage<sup>14</sup>. This was  
78 due, in part, to the higher infectiousness and severity of this virus variant<sup>15,16</sup>, partial immune  
79 evasion<sup>17</sup>, and, critically, waning vaccine immunity. Waning immunity was evident in both  
80 levels of neutralizing antibodies and studies of vaccine effectiveness, including for severe  
81 disease in older individuals<sup>18,19</sup>. To address the surge in COVID-19 in autumn 2021, third  
82 vaccine doses were offered to older ages and at risk individuals, but were not initially offered to  
83 healthy younger individuals because VE for severe disease in these age groups remained  
84 relatively high<sup>20</sup>. However, the potential impacts of offering third doses to all individuals to  
85 reduce transmission was not considered because of a lack of information on the benefits of  
86 indirect protection<sup>21</sup>.


87           Here we estimate the potential impact of third doses of mRNA vaccines on population-  
88 level transmission of the Delta variant in late 2021 and the number of deaths that could have  
89 been averted. We first estimated how  $VE_S$  and  $VE_I$  change over time due to waning and boosting  
90 of immunity. Previous work has demonstrated strong correlations between a surrogate measure  
91 of protection, neutralizing antibody titers, and VE for symptomatic and severe disease<sup>22-27</sup>, and  
92 one study used these relationships to examine the impacts of vaccination for averting disease and  
93 deaths<sup>26</sup>. Here, we extend this approach by developing the first relationships, for any pathogen,  
94 between neutralizing antibody titers and  $VE_S$  and  $VE_I$ , which are required to estimate the impact  
95 of vaccination on transmission. We then quantified relationships between neutralizing antibody  
96 titers and time since vaccination, and following boosting with a third dose of mRNA vaccines.  
97 We integrated these two relationships to estimate the potential impacts of deploying additional

98 vaccine doses on the reproductive number of the virus,  $R_t$ , under multiple scenarios. Finally, we  
99 estimated the number of Delta infections and deaths that could have been averted in the United  
100 States in Autumn 2021 by deploying third doses to reduce transmission.

101

## 102 Results

103 We found very strong relationships between variant- and vaccine-neutralizing antibody  
104 titer ratios ( $NATR_{tot}$ ) and VE using 23 estimates of VEs (susceptibility) and 14 estimates of  $VE_I$   
105 (infectiousness) across three variants and four vaccines (Figure 1A,B; Table S1). VEs was higher  
106 than  $VE_I$  across the range of  $NATR_{tot}$  observed, but the slope of  $VE_I$  was higher (VE increased  
107 more rapidly as  $NATR_{tot}$  values increased) (Figure 1; Table S1).



108


109 **Fig. 1. Vaccine Effectiveness (VE) plotted against variant- and vaccine-specific neutralizing**  
110 **antibody titer ratios (NATR<sub>tot</sub>) for (A) susceptibility, VE<sub>S</sub>, (B) infectiousness, VE<sub>I</sub>, and (C)**  
111 **transmission VE<sub>T</sub>. Each point (and 95% CI) represents a single empirical estimate of VE**  
112 **for a single vaccine (or infection) & virus variant. Points are jittered slightly along the x-**  
113 **axis to facilitate presentation. Black lines and ribbons in (A) and (B) show the fitted model**  
114 **and 95% CIs. The line and 95% CI ribbon in (C) is estimated from lines in (A) and (B):**  
115  **$VE_T = 1 - (1 - VE_S) * (1 - VE_I)$ ; see Methods for details.**

116 In the eight months after vaccination, neutralizing antibody titers waned approximately 8-  
117 fold for vaccine-derived immunity for both BNT162b2 and mRNA-1273 vaccines and 3-fold for  
118 infection derived immunity, with most waning occurring in the first 3-5 months (Figure 2A, B;  
119 Table S2). Rates of waning were faster for the BNT162b2 vaccine than the mRNA-1273 vaccine  
120 and infection-derived immunity (Figure 2B; Table S2). Initial neutralizing antibody titers were  
121 highest for vaccination with mRNA-1273, followed by BNT162b2, and lowest following  
122 infection (Figure 2A; Table S2).

123 We used the relationships between neutralizing antibody titers and VE (Figure 1) and  
124 patterns of waning of antibody titers (Figure 2A, B) to estimate the waning of VE<sub>S</sub> and VE<sub>I</sub> over  
125 time (Figure 2C, D). As expected from levels of antibody titers, VE<sub>S</sub> and VE<sub>I</sub> were highest for  
126 two-dose vaccination with mRNA-1273, and BNT162b2 vaccines, and then infection-derived  
127 immunity (Figure 2C, D). The relatively fast waning rate of neutralizing antibodies for the  
128 BNT162b2 vaccine suggests that VE for this vaccine was initially much higher than infection-  
129 derived immunity, but the two were similar after 3-4 months (Figure 2C, D). VE for the mRNA-  
130 1273 vaccine remained higher than both the BNT162b2 vaccine and previous infection as  
131 protection waned (Figure 2C, D).

132           A third dose of the BNT162b2 vaccine boosted antibody titers 26-fold relative to levels  
133 after 8 months of waning, or  $25.9/8.1 = 3.2$ -fold higher than one week after dose two<sup>28</sup>. A third  
134 dose of the mRNA-1273 vaccine boosted antibody titers 13-fold relative to 8-month waned  
135 levels, or 1.5-fold higher than shortly after the second dose. The fitted relationship between VEs  
136 and neutralizing antibody titer ratios (Figure 1) suggested that third doses of the mRNA vaccines  
137 would increase VEs 1.6-1.8-fold from waned values of 47-54% to boosted values of 85-86% and  
138 would boost VE<sub>I</sub> 3-4-fold from 16-22% to 65-68% (Table S3; Figure 2C,D; compare blue and  
139 purple points in upper right of panels to lines of the same color below). Combined, boosting  
140 waned individuals with a third vaccine dose increased VE for transmission ( $VE_T = 1 - (1 - VE_S) * (1 -$   
141  $VE_I)$ ) from 55.4% to 95.4% for BNT162b2 and from 64.3% to 94.5% for mRNA-1273. In doing  
142 so, boosting reduced the risk of transmission ( $1 - VE_T$ ) by ~10-fold or 89.7% for BNT162b2 and  
143 ~7-fold or 84.5% for mRNA-1273 vaccinated individuals compared to waned immunity.






144

145 **Figure 2. Waning of neutralizing antibody titers and VE for susceptibility ( $VE_s$ ) and**  
146 **infectiousness ( $VE_i$ ) over time and following boosting with a third dose. Lines show fitted**  
147 **models and ribbons show  $\pm 1$  SE (Table S1). A) Neutralizing antibody titers relative to**  
148 **convalescent sera with wild-type (WT) virus, adjusted for the 2.2-fold lower neutralization**  
149 **titers with the Delta variant relative to wild-type virus. B) The same data as in panel A but**  
150 **rescaled relative to the initial peak value (i.e. all lines start at a value of 1) to show relative**

151 **rates of waning and levels of stabilization (Table S1). C) VE for susceptibility (VE<sub>s</sub>) over**  
152 **time using the patterns of waning in Panel A and the relationships between antibody titers**  
153 **and VE for susceptibility (Figure 1A). D) VE for infectiousness (VE<sub>I</sub>) over time using the**  
154 **patterns of waning in Panel A and the relationships between antibody titers and VE for**  
155 **infectiousness (Figure 1B). Points in the upper righthand corner of panels C and D,**  
156 **indicated by the black arrows, show the effect of third doses in boosting VE for the**  
157 **BNT162b2 and mRNA-1273 vaccines.**

158         Next, we examined the impacts of third doses on population-level transmission in the  
159 United States via reductions in the reproductive rate of the pathogen,  $R_t$ . On September 1, 2021,  
160 the average time since vaccination for vaccinated individuals (53.2% of the population) was 4  
161 months (118.3 days) (Figure S1) resulting in average antibody titers waning to less than 22% of  
162 peak values. If all doubly vaccinated individuals in the USA received a third dose of an mRNA  
163 vaccine that took effect on 1 September 2021 this would have reduced  $R_t$  by 18.4% (95% CI:  
164 15.0% to 21.8%) from 1.17 to 0.96 (Figure 3D). This would have stopped the strong surge in  
165 cases, hospitalizations, and deaths that occurred over the next few months, assuming contact  
166 rates and other behaviors didn't change following boosting (see Methods for further details).  
167 Notably, using the same number of doses to doubly vaccinate unvaccinated individuals  
168 (assuming they were willing to be vaccinated) rather than boost previously vaccinated  
169 individuals would have been similarly effective in reducing transmission ( $R_t$  would decrease  
170 from 1.17 to 0.94 versus 1.17 to 0.96 for using doses for boosting vaccinated individuals) (Figure  
171 3D, compare right end of red line to red point labeled " $R_0 = 3.2$ , 79.8% vacc., no 3<sup>rd</sup> doses" on  
172 left side). We also explored several other scenarios with varying vaccination and infection rates  
173 and contact rates, which showed that the percent reduction in  $R_t$  was driven primarily by the

174 fraction of the population vaccinated, which determined the potential boosting fraction  
175 (Supplemental Results Text, Figure S2).




176

177 **Figure 3. United States population vaccination and infection history over time, population-**  
178 **level vaccine effectiveness against susceptibility ( $VE_S$ ) and infectiousness ( $VE_I$ ) over time,**  
179 **and the relationship between the pathogen effective reproductive number,  $R_t$  and third**  
180 **dose coverage, as of 1 September, 2021. A) Fraction of the US population that had received**

181 **their primary vaccination series but had not been infected (Frac. Vacc.), had been infected**  
182 **but not vaccinated (Frac. Inf.), had been both vaccinated and infected (Frac. Hybrid), or**  
183 **had received their third-dose booster (Frac. Boost). B) and C) Lines  $\pm 1$  SE show**  
184 **population-level VE against susceptibility (B) and infectiousness (C) over time for three**  
185 **subpopulations (vaccinated with their primary series, previously infected, and both**  
186 **vaccinated and previously infected [hybrid]) and the entire population in the US (“Total”)**  
187 **which is a mixture of the five subpopulations, as shown in panel (A). Rectangles above**  
188 **panels (A-C) show which variant was dominant during the period (frequency  $\geq 50\%$ ). D)**  
189 **Line  $\pm 1$  SE shows  $R_t$  plotted against the fraction of vaccinated individuals receiving third**  
190 **dose boosters for the United States with  $R_0=3.2$ , 53.2% vaccinated, and 67.4% previously**  
191 **infected as of September 1, 2021 (see Methods for additional details). The single red point**  
192 **shows the impact of using all third doses from the right end of the red line to doubly-**  
193 **vaccinate unvaccinated individuals, which would bring the vaccination coverage from**  
194 **53.2% to 79.8%. The dashed horizontal line shows the threshold reproductive number  $R_t =$**   
195 **1, separating growing from shrinking epidemics.**

196       Between June 2021, when the Delta variant emerged, and January 2022, the Delta variant  
197 caused an estimated 273,801 deaths<sup>14</sup>, with the average number of estimated daily cases  
198 sometimes exceeding 200,000 (Figure S3), and reported deaths sometimes exceeding 2,000/day  
199 (Figure 4). However, during this period the estimated  $R_t$  for the US population mostly fluctuated  
200 between 0.9 and 1.1 (Figure S3), suggesting that many thousands of deaths could have been  
201 prevented if  $R_t$  could have been reduced, even marginally. As we just illustrated, boosting the  
202 53.2% of the population that had been vaccinated with a third dose by 1 September, 2021 would  
203 have reduced  $R_t$  by 18.4% (Figure 3D, red line). This would have reduced the number of Delta

204 deaths by 111,525 (95% CI: 103,819 to 116,641) (Figure 4E, blue shaded region) by averting  
205 37,174,963 infections (95% CI: 34,606,246 – 38,880,500) (Figure 4A, orange shaded region).  
206 Boosting with third doses could have averted 629.5 (95% CI: 586.0 to 658.3) deaths per million  
207 vaccine doses administered due to effects on transmission alone.



208  
209 **Figure 4. Estimated daily infections (A-D) and reported or estimated deaths (E-H) with and**  
210 **without third dose boosting plotted against time in the United States when the Delta SARS-**  
211 **CoV-2 variant was dominant. Black lines in the left panels show the estimated number of**  
212 **infections each day, calculated by deconvolution using the observed daily deaths (dark blue**  
213 **lines in right panels) and the delays between infection and death, and using an**  
214 **infection fatality ratio (IFR) of 0.003<sup>29</sup>. Deaths from the Delta variant were estimated using**  
215 **reported deaths and variant fractions based on sequencing data (see Methods). Red lines in**  
216 **left panels show the estimated number of infections with third dose boosting, and light blue**  
217 **lines show the number of deaths resulting from these infections with the timing estimated**

218 **by reconvolution given the same distributions. The shaded regions show the averted**  
219 **infections (orange) and deaths (blue) if all eligible vaccinees received third doses that took**  
220 **full effect on Sept. 1, Oct. 1, Nov. 1, or Dec. 1 as indicated on the panel title with the**  
221 **reduction in  $R_t$  for these dates shown in Figure S2.**

222 Boosting populations after Sept. 1 would have resulted in greater reductions in  $R_t$  as  
223 immunity in the vaccinated group continued to wane but would avert fewer deaths caused by the  
224 Delta variant. Boosting on October 1, November 1, or December 1 would have reduced  $R_t$  by  
225 29.7%, 31.2%, and 30.0%, respectively (Figure S2), but would avert 73,574 (95% CI: 69,253 –  
226 75,962), 36,424 (95% CI: 33,085 – 38,350) and 5,970 (95% CI: 5,039 – 6,617) Delta deaths  
227 (Figure 4; Table S5).

228

## 229 **Discussion**

230 The indirect effects of vaccination in reducing disease by reducing transmission (via  
231 reduced susceptibility or infectiousness) were rarely considered at any stage of COVID-19  
232 vaccination programs, including initial trial design, initial vaccination, and subsequent boosting.  
233 We found that boosting population immunity with third vaccine doses could have substantially  
234 reduced transmission of the most deadly SARS-CoV-2 variant, Delta, stopped surges, and  
235 averted huge numbers of deaths in many populations, including more than 100,000 in the US.  
236 We estimated that 629 deaths could have been averted per million vaccine doses which is similar  
237 to or higher than the direct effects of COVID-19 vaccination in other studies (93 to 836 deaths  
238 per million doses administered<sup>30–33</sup>). However, many countries initially offered third doses only  
239 to protect at-risk individuals and only later offered third doses to the general population<sup>20</sup>.  
240 Likely as a result, third dose uptake by the general population in most countries was low. It may

241 have been higher if the third dose boosters were immediately and strongly recommended, or  
242 mandated for the whole population <sup>34</sup>.

243 The approach we developed here provides an empirical framework for estimating the  
244 effect of vaccination on transmission in a dynamic immune landscape. The key components are  
245 the temporal dynamics of a surrogate of protection neutralizing antibody titers and relationships  
246 between neutralizing antibody titers and the two components of transmission: susceptibility and  
247 infectiousness. Previous studies have shown that neutralizing antibody titers were strongly  
248 correlated with VE for symptomatic disease and severe disease <sup>22-24,26,27</sup>. Here, we significantly  
249 advanced this approach by showing that antibody titers were also strongly correlated with VEs  
250 and VE<sub>I</sub>. This advance is critical for building accurate mathematical models of SARS-CoV-2  
251 transmission as immunity wanes and is boosted with additional vaccine doses or infection.  
252 Previous models have assumed VE for transmission was the same as VE for symptomatic  
253 disease<sup>26</sup>, which underestimates susceptibility (the relative risk of infection) and underestimates  
254 transmission (Figure S4). A similar empirical framework for estimating the effect of vaccination  
255 on transmission could be developed for other pathogens, such as influenza virus, but it would  
256 require a surrogate of protection<sup>35</sup> and multiple estimates of vaccine efficacy for susceptibility  
257 and infectiousness in population with different levels of immunity.

258 We found that VEs and VE<sub>I</sub> declined rapidly in the first 3-5 months post-vaccination in  
259 BNT162b2 recipients and plateaued after ~6 months, with slower, waning in mRNA-1273  
260 recipients, which may or may not be related to long lasting plasma cells <sup>36,37</sup>. These rates of  
261 waning suggest that vaccinating individuals multiple times per year would have substantially  
262 increased VE for transmission against the Delta variant, and would likely increase VE for  
263 transmission for the currently circulating SARS-CoV-2 variants as well. Given the summer

264 surges of COVID-19 hospitalizations that now appear to be a repeatable phenomenon,  
265 recommending two vaccine doses per year for COVID-19, especially in sensitive settings such as  
266 skilled nursing facilities, could provide substantial benefits.

267 We found third vaccine doses could have reduced Delta deaths dramatically, but the  
268 impact depended on the timing when doses were administered. Rolling out third doses by  
269 September 1 would have averted an additional 37,951 Delta deaths in the US compared to  
270 waiting until October 1, which emphasizes the timeliness of vaccinations. Two related factors  
271 made a September 1 rollout especially impactful. First, infections were near their peak in  
272 September. Second,  $R_t$  was below 1.03 from September 1 until late November when the Omicron  
273 variant began to invade. The potential reduction in  $R_t$  due to third doses (18.4%) was sufficient  
274 to reduce  $R_t$  well below 1 which would have driven Delta infections and deaths down rapidly  
275 (Figure 4). Administering third doses later would have averted fewer deaths caused by the Delta  
276 variant (but may have averted additional infections and deaths caused by the Omicron variant).

277 Our study has several limitations. First, our analyses use population averages for  
278 estimates of  $VE_s$  and  $VE_t$  and ignore age-specific variation among individuals, as well as other  
279 factors. Age-specific patterns of contact, disease severity, and immunity can play a key role in  
280 shaping epidemics<sup>38</sup>. We also assumed well-mixed populations in calculating reductions in the  
281 reproductive number  $R_t$ . A targeted vaccination approach would be more effective than that  
282 outlined here if highly connected individuals could be targeted for third doses<sup>39</sup>. Third, our  
283 calculations for the reductions in  $R_t$  with third doses were based on neutralizing antibody titers  
284 one month after the administration of a third dose. Neutralizing antibody titers also decay  
285 following third doses, but the decay rate is much slower than after second doses<sup>40</sup>, suggesting  
286 that substantial reductions in  $R_t$  from third doses would persist for many months, as we assumed



287 here. Fourth, our analyses were focused on population characteristics in the US in late 2021 and  
288 vaccine effectiveness against the Delta variant because data were available for quantifying  
289 immunity in populations at this time. The current impact of vaccine doses on transmission of  
290 SARS-CoV-2 is more difficult to quantify with currently available data, due to a more complex  
291 immune landscape, with most people having been infected several times with multiple virus  
292 variants and vaccinated with multiple vaccine types, and the variant composition of SARS-CoV-  
293 2 viruses is sometimes diverse and changes frequently. Determining the current benefit of  
294 vaccination for reducing transmission would require estimates of the distribution of neutralizing  
295 antibody titers against currently circulating viruses in target populations, and measuring  
296 increases in antibody titers following vaccination. Finally, quantifying the impact of vaccination  
297 in reducing deaths due to reduced transmission does not take into account additional benefits of  
298 reduced infections including reduced absenteeism from work and school and reduced cases of  
299 long COVID. The total benefits of reduced transmission may outweigh the costs of administering  
300 additional vaccine doses in many populations.

301 In summary, we showed that the indirect benefits of vaccination in reducing transmission  
302 can lead to a huge number of deaths averted. In addition, reductions in transmission increase  
303 health equity by reducing infection in individuals that lack access to vaccination. Quantifying  
304 vaccine impacts on transmission should be an integral part of developing new vaccines, and  
305 estimates of reductions in transmission should be used for planning vaccination strategies,  
306 including vaccine selection, targeting, and vaccination schedules.

307

## 308 **Methods**

309 *Relative neutralizing antibody titers by variant, vaccine dose and with waning*

310 We collected data on neutralizing antibody titers from the literature and estimated the  
311 total neutralizing antibody titer ratio ( $\text{NATR}_{\text{tot}}$ ) for each vaccine, virus variant, and immune  
312 status<sup>24</sup>.  $\text{NATR}_{\text{tot}}$  is the ratio of neutralizing antibody titer for a given vaccine, variant and  
313 immune status, relative to the neutralizing antibody titer of convalescent sera after infection with  
314 the original wild-type virus<sup>24,27</sup>. For example, two weeks after a second dose of the BNT162b2  
315 vaccine  $\text{NATR}_{\text{tot}}$  for the Delta variant is 1.08, because vaccination with BNT162b2 results in  
316 neutralizing antibody titers 2.37-fold higher than infection<sup>24,27</sup>, and neutralizing antibody titers  
317 against the Delta variant are 2.20-fold lower than against wild-type virus;  $2.37 \times (1/2.2) = 1.08$ <sup>24</sup>.  
318 We also collected data from studies measuring neutralizing antibody titers over time in sets of  
319 individuals following infection or vaccination to quantify waning of neutralizing antibody titers,  
320 as well as increases in antibody titers following boosting with third doses<sup>28,41,42</sup>. We then fit  
321 models to the decay in antibody titers over time following vaccination with two mRNA vaccines  
322 (BNT162b2 and mRNA-1273), and infection (Table S1). We assumed antibody titers from  
323 hybrid immunity (infection followed by vaccination) waned at the same rate as following BNT  
324 162b2 vaccination based on a study that measured both<sup>42</sup>.

325

### 326 *VE for susceptibility and infectiousness*

327 We collected VE estimates for susceptibility and infectiousness for SARS-CoV-2 from  
328 the literature, including a systematic living review<sup>43</sup>, and categorized each study by vaccine,  
329 time since vaccination, and variant type (wild-type/D614G, Alpha, Delta). We excluded  
330 estimates where the virus variant could not be determined. For estimates of VEs, we only  
331 included studies where the endpoint was “all infections” (often measured using frequent testing  
332 or serology) and excluded studies where the endpoint was “any infection” because “any

333 infection” studies do not capture all infections and include an unknown fraction of asymptomatic  
334 infections. Studies of VE<sub>I</sub>, or transmission given infection, usually compared secondary attack  
335 rates in households by vaccination status of the index case.

336 To fit a relationship between VE and NATR, we needed estimates of the number of  
337 infections in the vaccine and control groups. However, most studies did not report the number of  
338 infections; however, all reported a VE and 95% CI. We estimated the effective number of  
339 infected individuals in the control group ( $I_c$ ) and the effective number of infected individuals in  
340 the vaccine group ( $I_v$ ) for each study by determining the number of each needed to match the  
341 mean and 95% CI given in a study. We held the effective number of individuals in the control  
342 group ( $N_c$ ) and vaccine group ( $N_v$ ) constant at 1,000,000 because the 95% CI was invariant to  
343 variation in these values for observed incidence values. We used a maximum value of 1000  
344 infections in the control group ( $I_c$ ) to reduce the undue leverage of some very large studies<sup>44</sup>.

345

#### 346 *Relationships between VE and neutralizing antibody titers by vaccine and variant*

347 We modeled the relationship between VE and total neutralizing antibody titer ratios  
348 ( $NATR_{tot}$ ) using<sup>24</sup>:

$$349 \quad VE = 1 - \frac{1}{1 + e^{-(c_0 + c_1 \log_2(NATR_{tot}))}} \quad (1)$$

350 We estimated the coefficients  $c_0$  and  $c_1$  separately for the two endpoints, susceptibility and  
351 infectiousness, by maximizing the likelihood of observing the data underlying the VE estimates:  
352 the number of infections in the control group,  $I_c$ , and vaccine group,  $I_v$ , for each study. The  
353 likelihood was the product of two binomial distributions with  $N_c$  and  $N_v$  individuals:

$$354 \quad L(N_c, I_c, N_v, I_v | NATR_{tot}, b_s, c_0, c_1) = Bi(N_c, I_c, b_s) * Bi(N_v, I_v, b_s * VE) \quad (2)$$

355 Here  $b_s$  is the baseline risk for the study period, which is the fraction of control individuals  
356 infected during the study. We maximized the likelihood across all studies which was the product  
357 of the likelihoods of the individual studies. We used the fitted relationships for the two  
358 endpoints, susceptibility and infectiousness, between VE and neutralizing antibody titer ratios,  
359  $NATR_{tot}$  (eq 1) to estimate VE for populations based on the estimated  $NATR_{tot}$  given the timing  
360 of vaccination and infection and estimated rates of waning as described above. Finally we  
361 calculated the VE for transmission,  $VE_T = 1 - (1 - VE_S) * (1 - VE_I)$ . We calculated 95% CIs for  $VE_T$   
362 using independent bootstrap samples from the  $VE_S$  and  $VE_I$  estimates and 95% CIs.

363

#### 364 *Vaccine effectiveness over time*

365 We estimated  $VE_S$  and  $VE_I$  in the US for each day from January 1, 2021 to December 13,  
366 2021 for three subpopulations: previously infected and unvaccinated, twice vaccinated and no  
367 previous infection, and twice vaccinated and previously infected (hybrid immunity), the timing  
368 of prior infections and vaccinations (Figure S1), and the relationships between neutralizing  
369 antibody titers and  $VE_S$  and  $VE_I$ . We estimated the timing of infections using reported deaths<sup>48</sup>  
370 and deconvolution, using the distributions for the delays between infection and death (i.e.  
371 infection to shedding, shedding to symptom onset, symptom onset to hospitalization, and  
372 hospitalization to death) (Table S6) using the deconvolve package in R<sup>45</sup>. For each day, we  
373 estimated  $VE_S$  and  $VE_I$  in each subpopulation against each circulating variant based on the  
374 timing of infections and vaccinations, accounting for the waning that occurred in each  
375 subpopulation on that date using the fitted model for the relationship between neutralizing  
376 antibodies and time since infection and vaccination. We used sequencing data from GISAID<sup>29,46</sup>  
377 (offset by 9 days to account for the average delay between infection and reporting date) in the

378 US to get a variant-averaged estimate of VEs and VE<sub>i</sub> in each subpopulation for each day using a  
379 weighted mean where weights were the observed variant frequency each day. We then estimated  
380 a population-wide VE for each day using estimates for the fraction of the population in five  
381 subpopulations: fully susceptible, third-dose boosted, and the three subpopulations described  
382 above.

383

#### 384 *The impact of third doses on the reproductive number, $R_t$*

385 We used patterns of waning and boosting of neutralizing antibody titers to estimate the  
386 impact of providing additional doses of mRNA vaccines to increasing fractions of vaccinated  
387 individuals in the USA and other populations on the reproductive number,  $R_t$ , of the Delta variant  
388 of SARS-CoV-2, at four time points in autumn 2021; Sept 1, Oct 1, Nov 1, and Dec 1 (Table  
389 S4).  $R_t$  is the average number of secondary cases that each case infects and is equal to the basic  
390 reproductive number for a pathogen in a fully susceptible population,  $R_0$ , multiplied by the  
391 fraction of the population that is susceptible (i.e. not immune from vaccination or previous  
392 infection).

393 We examined the effect of boosting vaccinated individuals with a third dose on  $R_t$  by  
394 considering five scenarios which were combinations of vaccination, previous infection and  
395 contact rates that span the range of circumstances in many countries in late 2021. The five  
396 scenarios (with fraction vaccinated and previously infected shown for 1 September 2021) and  
397 rationale were (Table S4):

- 398 1) US/D (United States with distancing):  $R_0 = 3.2$ , 53.2% vaccinated, 67.4% previously  
399 infected: approximated fraction of US population previously infected with contact rates  
400 similar to summer-fall 2021
- 401 2) CA/D (California, USA, with distancing):  $R_0 = 3.2$ , 58.7% vaccinated, 59.8% previously  
402 infected: approximated some populations with higher vaccination and lower fraction  
403 infected than scenario (1) (e.g. California)
- 404 3) NZ/ND (New Zealand, no distancing):  $R_0 = 7.0$ , 24.3% vaccinated, 0.2% previously  
405 infected: approximated countries with high vaccination rates that effectively suppressed  
406 transmission and had reduced contact rates when cases were detected (e.g. New Zealand,  
407 Australia, Hong Kong, etc.)
- 408 4) US/ND (United States, no distancing):  $R_0 = 7.0$ , 53.2% vaccinated, 67.4% previously  
409 infected: a scenario to compare to scenario (1) to determine if boosting could limit  
410 transmission if behavior returned to pre-pandemic levels
- 411 5) US/ND-100 (United States, no distancing):  $R_0 = 7.0$ , 100% vaccinated, 67.4% previously  
412 infected: a hypothetical optimistic scenario to compare to scenario (1) to determine if  
413 vaccination with or without boosting could limit transmission if behavior returned to pre-  
414 pandemic levels

415 We estimated the fraction of the population that was susceptible using data on the fraction of  
416 the population that had been vaccinated or infected or both. We first split each population into  
417 three groups based on vaccination status: fraction unvaccinated,  $f_U$ , fraction vaccinated,  $f_V$ , with  
418 two doses of either BNT162b2 or mRNA-1273, and fraction boosted with a third dose of the  
419 same vaccine used for the primary series,  $f_B$  ( $f_U + f_V + f_B = 1$ ). We calculated the fraction of people  
420 in the USA receiving BNT162b2 and mRNA-1273 from vaccination records<sup>47</sup>. We estimated the

421 timing of infections using deconvolution of deaths as described above and calculated the number  
422 of infections by dividing deaths by an estimate of the infection fatality ratio (IFR) across of  
423 2020-21 of 0.003<sup>29</sup>; the results were not sensitive to moderate variation in this estimate. We also  
424 examined estimating infections using cases and an infection/case ratio of 4.0<sup>48</sup> which produced a  
425 lower estimate of total infections, and the reduction in  $R_t$  with third dose boosting and deaths  
426 averted were very similar to the death-deconvolution and IFR method. We estimated the fraction  
427 of unvaccinated or vaccinated individuals that had been previously infected using the ratios of  
428 cases in these two groups over time in the USA<sup>49</sup> (Figure S5). We used vaccination and  
429 infection data to calculate the fraction of people previously infected among unvaccinated,  $f_{PU}$ ,  
430 and vaccinated,  $f_{PV}$  individuals (Table S4). We used rates of waning of antibody titers and data  
431 on the timing of vaccination and infection from the USA and New Zealand<sup>47</sup> for US and New  
432 Zealand scenarios, respectively, to estimate the distribution of  $NATR_{tot}$  in populations for the  
433 four time points in autumn 2021. We used the distributions of  $NATR_{tot}$  to estimate the relative  
434 susceptibility,  $1-VE_S$ , (Figure 1A) and relative infectiousness,  $1-VE_I$ , (Figure 1B) for the  
435 population in each of four groups: unvaccinated and previously infected ( $VE_{SP}$  and  $VE_{IP}$ ),  
436 vaccinated twice and no previous infection ( $VE_{SV}$  and  $VE_{IV}$ ), vaccinated three times or boosted  
437 ( $VE_{SB}$  and  $VE_{IB}$ ), and vaccinated and infected or hybrid immunity ( $VE_{SH}$  and  $VE_{IH}$ ), all with  
438 appropriate adjustments for waning antibody titers (see below). We used these estimates of  $VE$   
439 to calculate  $R_t$  for populations composed of different fractions of five groups: never infected  
440 unvaccinated  $(1-f_{PU})f_U$ , previously infected unvaccinated  $f_{PU}$ , previously uninfected vaccinated  
441 with two doses  $(1-f_{PV})f_V$ , previously infected and vaccinated with two doses  $f_{PV}f_V$ , and boosted  
442 with a third dose, regardless of previous infection,  $f_B$ :

$$R_t = R_0 [ (1-f_{PU})f_U + f_{PU}f_U(1-VE_{SP})(1-VE_{IP}) + (1-f_{PV})f_V(1-VE_{SV})(1-VE_{IV}) + (f_{PV}f_V)(1-VE_{SH})(1-VE_{IH}) + (f_B)(1-VE_{SB})(1-VE_{IB}) ] \quad (3)$$

Note that in equation (3) the VE values for each population are integrated across the distribution of NATR<sub>tot</sub> values for that group, and the distribution of NATR<sub>tot</sub> values in each group reflects the timing of vaccination and infection on a daily timestep.

We used the scenario estimates of the fraction of population with different types of immunity (with timing matched to vaccination and infection and waning as described above) for susceptibility and infectiousness to estimate values of  $R_t$  under each scenario at the four time points in autumn 2021 (Sept. 1, Oct. 1, Nov. 1, and Dec. 1; Table S4). We calculated 95% CIs for predicted values of  $R_t$  that incorporated uncertainty in the relationship between time since vaccination or infection and NATR<sub>istatus</sub>, uncertainty in the relationships between neutralizing antibody titers and VEs and VE<sub>I</sub>, as well as uncertainty in NATR<sub>vac</sub> and NATR<sub>var</sub> (Figures 1 and S2).

#### *The impact of third doses on infections and deaths caused by the Delta variant*

We estimated the timing of the infections that gave rise to observed deaths and total infections in the United States in autumn 2021 using deconvolution as described above. We used SARS-CoV-2 sequencing data<sup>29,46</sup> to estimate the daily fraction of all infections that were caused by the Delta variant. We estimated the reduction in Delta infections if third-dose boosters were given to all fully vaccinated individuals at four time points in autumn 2021. We assumed the additional doses would take full effect simultaneously on Sept. 1, Oct. 1, Nov. 1, or Dec. 1. We estimated the number of Delta infections that would have occurred if third doses had been



465 deployed by multiplying the number of estimated infections on each day by the reduction in the  
466 daily  $R_t$  due to third doses (e.g. 0.812 if  $R_t$  was reduced by 18.8%), raised to the power of the  
467 number of generations of infections (generation time 3.8d<sup>50</sup>) since Sept 1 (or Oct. 1, Nov. 1 or  
468 Dec. 1). The calculated reduction in  $R_t$  was the difference between the number of actual third-  
469 doses given, and the number of doses deployed in the scenario. We estimated the number of  
470 deaths that would have been averted in each scenario by re-convoluting the reduced infections,  
471 multiplied by the IFR, using the delays described previously. We used uncertainty associated  
472 with our  $R_t$  estimates to calculate 95% CIs in the number of deaths averted.

473

#### 474 **Author Contributors**

475 BJG and AMK conceived the study, performed the analyses and wrote the paper.

#### 476 **Declaration of competing interests**

477 All authors declare no competing interests.

#### 478 **Data sharing**

479 All data used in the paper are contained in the supplemental material.

480 R Code and data files to replicate the figures and analyses of this paper are available:

481 <https://github.com/marmkilpatrick/Vaccine-boosters>

482 Upon publication, R Code will be uploaded to Zenodo and data files will be archived with

483 Dryad.

#### 484 **Acknowledgements**

#### 485 **Funding**

486 We received funding from the National Science Foundation (DEB- 1911853, 1115895, and  
487 1717498) and the California Department of Health.

488

## 489 **References**

- 490 1 Allen A. Vaccine—the controversial story of medicine’s greatest lifesaver. New York, NY:  
491 W.W. Norton & Co., 2007.
- 492 2 Minor PD. Live attenuated vaccines: Historical successes and current challenges. *Virology*  
493 2015; **479–480**: 379–92.
- 494 3 Greenwood B. The contribution of vaccination to global health: past, present and future. *Phil*  
495 *Trans R Soc B* 2014; **369**: 20130433.
- 496 4 Hinman AR, Orenstein WA, Schuchat A. Vaccine-preventable diseases, immunizations, and  
497 MMWR--1961-2011. *MMWR Suppl* 2011; **60**: 49–57.
- 498 5 Roush SW. Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable  
499 Diseases in the United States. *JAMA* 2007; **298**: 2155.
- 500 6 Hudgens MG, Gilbert PB, Self SG. Endpoints in vaccine trials. *Stat Methods Med Res* 2004;  
501 **13**: 89–114.
- 502 7 Li X, Mukandavire C, Cucunubá ZM, *et al.* Estimating the health impact of vaccination  
503 against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a  
504 modelling study. *The Lancet* 2021; **397**: 398–408.
- 505 8 COVID-19: Developing Drugs and Biological Products for Treatment or Prevention. 2023.  
506 [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-products-treatment-or-prevention)  
507 [developing-drugs-and-biological-products-treatment-or-prevention.](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-products-treatment-or-prevention)
- 508 9 CDC. Child and Adolescent Immunization Schedule by Age. 2023.  
509 [https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html.](https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html)
- 510 10 CDC. Direct and indirect effects of routine vaccination of children with 7-valent  
511 pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United  
512 States, 1998-2003. 2005. [https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5436a1.htm.](https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5436a1.htm)
- 513 11 Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. 1985.
- 514 12 Medlock J, Galvani AP. Optimizing Influenza Vaccine Distribution. *Science* 2009; **325**:  
515 1705–8.
- 516 13 Marmot M. Achieving health equity: from root causes to fair outcomes. *The Lancet* 2007;  
517 **370**: 1153–63.

- 518 14 Walker J, Grubaugh ND, Gonsalves G, Pitzer V, Rizvi Z. One Million and Counting:  
519 Estimates of Deaths in the United States from Ancestral SARS-CoV-2 and Variants. *medRxiv*  
520 2022; : 2022.05.31.22275835.
- 521 15 Campbell F, Archer B, Laurenson-Schafer H, *et al.* Increased transmissibility and global  
522 spread of SARS-CoV-2 variants of concern as at June 2021. *Eurosurveillance* 2021; **26**.  
523 DOI:10.2807/1560-7917.ES.2021.26.24.2100509.
- 524 16 Elliott P, Haw D, Wang H, *et al.* Exponential growth, high prevalence of SARS-CoV-2, and  
525 vaccine effectiveness associated with the Delta variant. *Science* 2021; **374**: eabl9551.
- 526 17 Planas D, Veyer D, Baidaliuk A, *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to  
527 antibody neutralization. *Nature* 2021; **596**: 276–80.
- 528 18 Lustig Y, Zuckerman N, Nemet I, *et al.* Neutralising capacity against Delta (B.1.617.2) and  
529 other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in  
530 health care workers, Israel. *Eurosurveillance* 2021; **26**. DOI:10.2807/1560-  
531 7917.ES.2021.26.26.2100557.
- 532 19 Wu K, Werner AP, Moliva JI, *et al.* mRNA-1273 vaccine induces neutralizing antibodies  
533 against spike mutants from global SARS-CoV-2 variants. *bioRxiv* 2021; published online Jan  
534 25. DOI:10.1101/2021.01.25.427948.
- 535 20 Bar-On YM, Goldberg Y, Mandel M, *et al.* Protection Across Age Groups of BNT162b2  
536 Vaccine Booster against Covid-19. *medRxiv* 2021; published online Oct 7.  
537 DOI:10.1101/2021.10.07.21264626.
- 538 21 Krause PR, Fleming TR, Peto R, *et al.* Considerations in boosting COVID-19 vaccine immune  
539 responses. *The Lancet* 2021; **398**: 1377–80.
- 540 22 Cromer D, Steain M, Reynaldi A, *et al.* Neutralising antibody titres as predictors of protection  
541 against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *The Lancet*  
542 *Microbe* 2022; **3**: e52–61.
- 543 23 Cromer D, Steain M, Reynaldi A, *et al.* Predicting vaccine effectiveness against severe  
544 COVID-19 over time and against variants: a meta-analysis. *Nat Commun* 2023; **14**: 1633.
- 545 24 Gardner BJ, Kilpatrick AM. Predicting Vaccine Effectiveness for Hospitalization and  
546 Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers.  
547 *Viruses* 2024; **16**. DOI:10.3390/v16030479.
- 548 25 Hogan AB, Doohan P, Wu SL, *et al.* Estimating long-term vaccine effectiveness against  
549 SARS-CoV-2 variants: a model-based approach. *Nat Commun* 2023; **14**: 4325.
- 550 26 Hogan AB, Wu SL, Toor J, *et al.* Long-term vaccination strategies to mitigate the impact of  
551 SARS-CoV-2 transmission: A modelling study. *PLoS Med* 2023; **20**: e1004195.

- 552 27Khoury DS, Cromer D, Reynaldi A, *et al.* Neutralizing antibody levels are highly predictive of  
553 immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021; **27**: 1205–11.
- 554 28Falsey AR, Frenck RW, Walsh EE, *et al.* SARS-CoV-2 Neutralization with BNT162b2  
555 Vaccine Dose 3. *N Engl J Med* 2021; **385**: 1627–9.
- 556 29Kilpatrick AM. Ecological and Evolutionary Insights About Emerging Infectious Diseases  
557 from the COVID-19 Pandemic. *Annu Rev Ecol Evol Syst* 2023; **54**: 171–93.
- 558 30Kayano T, Sasanami M, Kobayashi T, *et al.* Number of averted COVID-19 cases and deaths  
559 attributable to reduced risk in vaccinated individuals in Japan. *The Lancet Regional Health -*  
560 *Western Pacific* 2022; **28**: 100571.
- 561 31Haas EJ, McLaughlin JM, Khan F, *et al.* Infections, hospitalisations, and deaths averted via a  
562 nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19  
563 vaccine in Israel: a retrospective surveillance study. *The Lancet Infectious Diseases* 2022; **22**:  
564 357–66.
- 565 32Santos CVBD, Noronha TGD, Werneck GL, Struchiner CJ, Villela DAM. Estimated COVID-  
566 19 severe cases and deaths averted in the first year of the vaccination campaign in Brazil: a  
567 retrospective observational study. *The Lancet Regional Health - Americas* 2023; **17**: 100418.
- 568 33Mendes D, Chapman R, Gal P, *et al.* Public health impact of booster vaccination against  
569 COVID-19 in the UK during Delta variant dominance in autumn 2021. *Journal of Medical*  
570 *Economics* 2022; **25**: 1039–50.
- 571 34Mello MM, Opel DJ, Benjamin RM, *et al.* Effectiveness of vaccination mandates in  
572 improving uptake of COVID-19 vaccines in the USA. *The Lancet* 2022; **400**: 535–8.
- 573 35Ward BJ, Pillet S, Charland N, Trepanier S, Couillard J, Landry N. The establishment of  
574 surrogates and correlates of protection: Useful tools for the licensure of effective influenza  
575 vaccines? *Human Vaccines & Immunotherapeutics* 2018; **14**: 647–56.
- 576 36Nguyen DC, Hentenaar IT, Morrison-Porter A, *et al.* SARS-CoV-2-specific plasma cells are  
577 not durably established in the bone marrow long-lived compartment after mRNA vaccination.  
578 *Nat Med* 2024; published online Sept 27. DOI:10.1038/s41591-024-03278-y.
- 579 37Schulz AR, Fiebig L, Hirsland H, *et al.* SARS-CoV-2 specific plasma cells acquire long-  
580 lived phenotypes in human bone marrow. *eBioMedicine* 2023; **95**: 104735.
- 581 38Yuan H-Y, Baguelin M, Kwok KO, Arinaminpathy N, Van Leeuwen E, Riley S. The impact  
582 of stratified immunity on the transmission dynamics of influenza. *Epidemics* 2017; **20**: 84–93.
- 583 39Firth JA, Hellewell J, Klepac P, Kissler S, Kucharski AJ, Spurgin LG. Using a real-world  
584 network to model localized COVID-19 control strategies. *Nat Med* 2020; **26**: 1616–22.

- 585 40 Gilboa M, Regev-Yochay G, Mandelboim M, *et al.* Durability of Immune Response After  
586 COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection. *JAMA*  
587 *Netw Open* 2022; **5**: e2231778.
- 588 41 Chu L, Vrbicky K, Montefiori D, *et al.* Immune response to SARS-CoV-2 after a booster of  
589 mRNA-1273: an open-label phase 2 trial. *Nat Med* 2022; **28**: 1042–9.
- 590 42 Goel RR, Painter MM, Apostolidis SA, *et al.* mRNA vaccines induce durable immune  
591 memory to SARS-CoV-2 and variants of concern. *Science* 2021; **374**: abm0829.
- 592 43 Higdon MM, Wahl B, Jones CB, *et al.* A Systematic Review of Coronavirus Disease 2019  
593 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus  
594 2 Infection and Disease. *Open Forum Infectious Diseases* 2022; **9**: ofac138.
- 595 44 Lewnard JA, Patel MM, Jewell NP, *et al.* Theoretical Framework for Retrospective Studies of  
596 the Effectiveness of SARS-CoV-2 Vaccines. *Epidemiology* 2021; **32**: 508–17.
- 597 45 Lewnard JA, Liu VX, Jackson ML, *et al.* Incidence, clinical outcomes, and transmission  
598 dynamics of hospitalized 2019 coronavirus disease among 9,596,321 individuals residing in  
599 California and Washington, United States: a prospective cohort study. 2020; published online  
600 April 16. DOI:10.1101/2020.04.12.20062943.
- 601 46 Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to  
602 reality. *Eurosurveillance* 2017; **22**. DOI:10.2807/1560-7917.ES.2017.22.13.30494.
- 603 47 Mathieu E, Ritchie H, Rodés-Guirao L, *et al.* Coronavirus Pandemic (COVID-19). Our World  
604 in Data. 2020.
- 605 48 CDC. Estimated COVID-19 Burden. 2021. <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html>.
- 606
- 607 49 COVID Data Tracker. CDC. 2021. <https://covid.cdc.gov/covid-data-tracker/>.
- 608 50 Park SW, Sun K, Abbott S, *et al.* Inferring the differences in incubation-period and  
609 generation-interval distributions of the Delta and Omicron variants of SARS-CoV-2.  
610 *Proceedings of the National Academy of Sciences* 2023; **120**: e2221887120.
- 611